Baxter International (NYSE:BAX) Coverage Initiated by Analysts at Barclays

Research analysts at Barclays began coverage on shares of Baxter International (NYSE:BAX) in a report issued on Wednesday, Benzinga reports. The firm set an “underweight” rating and a $20.00 price target on the medical instruments supplier’s stock. Barclays‘s price target suggests a potential downside of 17.72% from the stock’s current price.

A number of other brokerages also recently issued reports on BAX. Weiss Ratings raised Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. UBS Group raised their target price on Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Wells Fargo & Company boosted their target price on Baxter International from $19.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. The Goldman Sachs Group increased their price target on shares of Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Finally, TD Cowen boosted their price objective on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, July 27th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Baxter International presently has a consensus rating of “Reduce” and a consensus target price of $21.73.

Baxter International Stock Up 0.4%

Shares of NYSE:BAX opened at $24.31 on Wednesday. Baxter International has a fifty-two week low of $15.73 and a fifty-two week high of $30.00. The firm’s 50 day moving average price is $25.34 and its 200 day moving average price is $21.43. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. The stock has a market cap of $12.57 billion, a price-to-earnings ratio of -11.74, a price-to-earnings-growth ratio of 3.66 and a beta of 0.65.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.80 billion. During the same quarter in the previous year, the business posted $0.59 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities research analysts predict that Baxter International will post 2.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Baxter International

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Baxter International during the 2nd quarter worth $1,744,874,000. Pzena Investment Management LLC purchased a new position in shares of Baxter International during the second quarter worth about $1,392,098,000. Equity Investment Corp acquired a new position in Baxter International in the 2nd quarter valued at about $146,815,000. Bank of America Corp DE acquired a new stake in Baxter International during the 2nd quarter worth approximately $132,993,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Baxter International in the 2nd quarter valued at approximately $68,036,000. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops and markets products used in hospitals, outpatient facilities and other care settings. Its portfolio includes intravenous solutions and administration sets, infusion pumps, parenteral nutrition products, injectable medicines, surgical products and systems for medication preparation and delivery.

The company also provides products and technologies that support anesthesia, critical care, patient monitoring and other hospital workflows.